# Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

> **NCT07108985** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hyperglycemia
- Insulin Resistance

## Interventions

- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Sitagliptin 100 mg + Dapagliflozin 10 mg
- **DRUG:** Sitagliptin 100 mg + Dapagliflozin 10 mg
- **DRUG:** Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

## Key facts

- **NCT ID:** NCT07108985
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2029-09-01
- **Final completion:** 2030-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108985, "Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07108985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*